Cardiac hypertrophy in mice expressing unphosphorylatable phospholemman

Cardiovascular Research

Volumn 104, Issue 1, 2014, Pages 72-82

  Boguslavskyi, Andrii ^a   Pavlovic, Davor ^a   Aughton, Karen ^a   Clark, James E ^a   Howie, Jacqueline ^b   Fuller, William ^b   Shattock, Michael J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Hypertrophy; Intracellular sodium; Na K ATPase; Phospholemman

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); MEMBRANE PROTEIN; PHOSPHOLEMMAN; PROTEIN; UNCLASSIFIED DRUG; PHOSPHOPROTEIN; SODIUM; SODIUM CALCIUM EXCHANGE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CATHETERIZATION; CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; MORPHOMETRICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SODIUM CELL LEVEL; TISSUE REGENERATION; WILD TYPE; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; DISEASE MODEL; GENE TARGETING; GENETICS; GENOTYPE; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MALE; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PHOSPHORYLATION; TIME FACTOR; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; GENOTYPE; HYPERTROPHY, LEFT VENTRICULAR; MALE; MEMBRANE PROTEINS; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PHENOTYPE; PHOSPHOPROTEINS; PHOSPHORYLATION; SODIUM; SODIUM-CALCIUM EXCHANGER; SODIUM-POTASSIUM-EXCHANGING ATPASE; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84913535052     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu182     Document Type: Article

References (35)

1. Tani M, Neely JR. Role of intracellular Na+ in Ca2+ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Possible involvement of H+-Na+and Na+-Ca2+ exchange. Circ Res 1989;65:1045-1056
2. Neubauer S, Newell JB, Ingwall JS. Metabolic consequences and predictability of ventricular fibrillation in hypoxia. A 31P- And 23Na-nuclear magnetic resonance study of the isolated rat heart. Circulation 1992;86:302-310
3. Pogwizd SM, Sipido KR, Verdonck F, BersDM.IntracellularNain animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis. Cardiovasc Res 2003; 57:887-896
4. Verdonck F, Volders PG, Vos MA, Sipido KR. Increased Na+ concentration and altered Na/K pump activity in hypertrophied canine ventricular cells. Cardiovasc Res 2003;57: 1035-1043
5. Verdonck F, Volders PG, Vos MA, Sipido KR. IntracellularNa+and alteredNa+transport mechanisms in cardiac hypertrophy and failure. J Mol Cell Cardiol 2003;35:5-25
6. Liu T, ORourke B. Enhancing mitochondrial Ca2+ uptake in myocytes from failing hearts restores energy supply and demand matching. Circ Res 2008;103:279-288
7. Pieske B, Maier LS, Piacentino V III, Weisser J, Hasenfuss G, Houser S. Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation 2002; 106:447-453
8. Despa S, Islam MA, Weber CR, Pogwizd SM, Bers DM. Intracellular Na(+) concentration is elevated in heart failure but Na/K pump function is unchanged. Circulation 2002; 105:2543-2548
9. Fuller W, Parmar V, Eaton P, Bell JR, Shattock MJ. Cardiac ischemia causes inhibition of the Na/K ATPase by a labile cytosolic compound whose production is linked to oxidant stress. Cardiovasc Res 2003;57:1044-1051
10. Fuller W, Howie J, McLatchie LM, Weber RJ, Hastie CJ, Burness K, Pavlovic D, Shattock MJ. FXYD1 phosphorylation in vitro and in adult rat cardiac myocytes: threonine 69 is a novel substrate for protein kinase C. Am J Physiol Cell Physiol 2009;296: C1346-C1355
11. Pavlovic D, Fuller W, Shattock MJ. Novel regulation of cardiacNapump via phospholemman. J Mol Cell Cardiol 2013;61:83-93
12. Fuller W, Tulloch LB, Shattock MJ, Calaghan SC, Howie J, Wypijewski KJ. Regulation of the cardiac sodium pump. Cell Mol Life Sci 2013;70:1357-1380
13. El-Armouche A, Eschenhagen T. b-Adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev 2009;14:225-241
14. Bers DM, Despa S, Bossuyt J. Regulation of Ca2+ and Na+ in normal and failing cardiac myocytes. Ann N Y Acad Sci 2006;1080:165-177
15. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, Probstfield JL, Yusuf S. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996; 94:690-697
16. Lohse MJ, Engelhardt S, EschenhagenT.Whatis the role ofb-Adrenergic signaling in heart failure?. Circ Res 2003;93:896-906
17. Nicolaou P, Hajjar RJ, Kranias EG. Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J Mol Cell Cardiol 2009;47:365-371
18. Schmidt AG, Edes I, Kranias EG. Phospholamban: a promising therapeutic target in heart failure?. Cardiovasc Drugs Ther 2001;15:387-396
19. Bossuyt J, Ai X, Moorman JR, Pogwizd SM, Bers DM. Expression and phosphorylation of the Na-pump regulatory subunit phospholemman in heart failure. Circ Res 2005;97: 558-565
20. El-Armouche A, Wittkodddpper K, Fuller W, Howie J, Shattock MJ, Pavlovic D. Phospholemman-dependent regulation of the cardiac Na/K-ATPase activity is modulated by inhibitor-1 sensitive type-1 phosphatase. FASEB J 2011;25:4467-4475
21. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, Shah AM. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 2003;93:802-805
22. Pavlovicaaa D, Fuller W, Shattock MJ. The intracellular region of FXYD1 is sufficient to regulate cardiac Na/K ATPase. FASEB J 2007;21:1539-1546
23. Despa S, Tucker AL, Bers DM. Phospholemman-mediated activation of Na/K-ATPase limits [Na]i and inotropic state during b-Adrenergic stimulation in mouse ventricular myocytes. Circulation 2008;117:1849-1855
24. Pavlovic D, Hall AR, Kennington EJ, Aughton K, Boguslavskyi A, Fuller W, Despa S, Bers DM, Shattock MJ. Nitric oxide regulates cardiac intracellular Na+ and Ca2+ by modulating Na/K ATPase via PKC1 and phospholemman-dependent mechanism. J Mol Cell Cardiol 2013;61:164-171
25. Zhang XQ, Ahlers BA, Tucker AL, Song J, Wang J, Moorman JR, Mounsey JP, Carl LL, Rothblum LI, Cheung JY. Phospholemman inhibition of the cardiacNa+/Ca2+exchanger: Role Of Phosphorylation. J Biol Chem 2006;281:7784-7792
26. Cheung JY, Rothblum LI, Moorman JR, Tucker AL, Song J, Ahlers BA, Carl LL, Wang J, Zhang XQ. Regulation of cardiac Na+/Ca2+ exchanger by phospholemman. Ann N Y Acad Sci 2007;1099:119-134
27. Akashi YJ, Nakazawa K, Sakakibara M, Miyake F, Koike H, Sasaka K. The clinical features of takotsubo cardiomyopathy. QJM 2003;96:563-573
28. Soltysinska E, Thiele S, Olesen SP, Osadchii OE. Chronic sympathetic activation promotes downregulation of beta-Adrenoceptor-mediated effects in the guinea pig heart independently of structural remodeling and systolic dysfunction. Pflugers Arch 2011;462: 529-543
29. Adachi-Akahane S, Lu L, Li Z, Frank JS, Philipson KD, Morad M.Calcium signaling in transgenic mice overexpressing cardiac Na(+)-Ca2+ exchanger. J Gen Physiol 1997;109:717-729
30. Correll RN, Eder P, Burr AR, Despa S, Davis J, Bers DM, Molkentin JD. Overexpression of the Na+/K+ATPase a2 but not a1 isoform attenuates pathological cardiac hypertrophy and remodeling. Circ Res 2014;114:249-256
31. Song J, Zhang XQ, Ahlers BA, Carl LL, Wang J, Rothblum LI, Stahl RC, Mounsey JP, Tucker AL, Moorman JR, Cheung JY. Serine 68 of phospholemman is critical in modulation of contractility, [Ca2+]i transients, and Na+/Ca2+ exchange in adult rat cardiac myocytes. Am J Physiol Heart Circ Physiol 2005;288:H2342-H2354
32. Shattock MJ, Bers DM. Rat vs. rabbit ventricle: Ca flux and intracellular Na assessed by ion-selective microelectrodes. Am J Physiol 1989;256:C813-C822
33. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533
34. Rasmussen HH, Figtree G. Dont flog the heart!-development of specific drug therapies for heart failure. Crit Care Resusc 2007;9:364-369
35. Shattock MJ. Phospholemman: its role in normal cardiac physiology and potential as a druggable target in Disease. Curr Opin Pharmacol 2009;9:160-166